The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $19.73

Today's change+0.20 +1.02%
Updated February 12 3:49 PM EST. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $19.73

Today's change+0.20 +1.02%
Updated February 12 3:49 PM EST. Delayed by at least 15 minutes.

Meridian Bioscience Inc Hits New 20-day High

Meridian Bioscience Inc closed up Friday by (U.S.)$0.20 or 1.02% to (U.S.)$19.73 and setting a new 20-day high. Over the last five days, shares have gained 5.28%, but are down 3.85% for the last year to date. Shares have outperformed the S&P 500 by 14.68% during the last year.

Key company metrics

  • Open(U.S.) $19.68
  • Previous close(U.S.) $19.53
  • High(U.S.) $19.75
  • Low(U.S.) $19.47
  • Bid / Ask(U.S.) $19.72 / (U.S.) $19.74
  • YTD % change-3.85%
  • Volume197,067
  • Average volume (10-day)317,264
  • Average volume (1-month)294,334
  • Average volume (3-month)244,088
  • 52-week range(U.S.) $16.60 to (U.S.) $21.23
  • Beta1.13
  • Trailing P/E22.75×
  • P/E 1 year forward21.98×
  • Forward PEG1.37×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.05%
  • Trailing EPS(U.S.) $0.87
Updated February 12 3:49 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.83%

Based on its net profit margin of 18.83%, Meridian Bioscience Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.37%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue47485248
Total other revenue--------
Total revenue47485248
Gross profit30303329
Total cost of revenue17181919
Total operating expense34343635
Selling / general / administrative14131313
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income13141613
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax13141612
Income after tax89108
Income tax, total5554
Net income89108
Total adjustments to net income--------
Net income before extra. items89108
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items89108
Inc. avail. to common incl. extra. items89108
Diluted net income89108
Dilution adjustment--------
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.200.220.240.19
Dividends per sharevalue per share0.200.200.200.20
Diluted normalized EPSvalue per share0.200.220.240.19